This was a really great lecture I am looking into a follow up seeing as this was a few years ago but it was fascinating thought I would share.

http://www.youtube.com/watch?v=uzw6_cWqdkY

I watched the whole thing, it was fascinating. I wonder what happened with this guys research?

I emailed the University to see if it ever made it human trials waiting for a response.

I also found this very interesting! Thanks for sharing it.

My mother has rheumatoid arthritis. I have a sister that has now been dx'd with ulcerative colitis. I have multiple sclerosis. My brother and myself have had psoriasis. My dad has Type 2 diabetes, so I don't know if that is included, and at the age of 77, just dx'd with the late form of leukemia.

There is something in our genes that is messing with our immune systems, obviously. It was interesting that three of our diseases are linked with the common T-cell part.

I can't wait to share this info with my family.

I found the company information on this it's a company called airmid and from the website I was able to find proof it has gone on to human testing. I was also able to find the email address for Dr. Chandy who gave this presentation I have emailed him to inquire how it is coming along.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Target Portfolio >> Proof-of-concept AIRMID Technology
In Humans:

* Disease-associated autoreactive T cells are effector-memory T cells with elevated Kv1.3 expression.
* PAP-1 and ShK-186 suppress effector memory T cell- proliferation and cytokine production without impacting naïve and central memory T cells.

In Animals:

* ShK-186 and PAP-1 ameliorate disease in many models of autoimmune disease
* Multiple sclerosis
o Adoptive experimental autoimmune encephalomyelitis
chronic relapsing-remitting EAE
o Rheumatoid arthritis pristane-induced arthritis
* Type-1 diabetes mellitus
o experimental autoimmune diabetes mellitu
* Contact dermatitis (and psoriasis)
o Acute allergic
o Contact dermatitis
* Other effector memory-mediated T cell
o Responses Delayed type hypersensit

Independent Confirmation:

Merck: Kv1.3 blockers suppress effector memory T cell-mediated delayed type hypersensitivity in animals. Harvard Dental School: Kv1.3 blocker ameliorated effector memory T cell-mediated experimental bone resorption associated with periodontitis. University of Marseille: Kv1.3 blocker ameliorated effector memory T cell-mediated adoptive experimental autoimmune encephalomyelitis and delayed-type hypersensitivity.



website: http://www.airmid.com/index.html